The FDA on Friday approved Mirum Pharmaceuticals' Ctexli to treat adults with cerebrotendinous xanthomatosis (CTX), a rare, progressive and genetic disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback